Answers are grounded in this paper and cite their sources.
Background Predicting the clinical behavior of intracranial meningiomas has traditionally relied on histopathological grading, although tumors with similar morphology often demonstrate markedly different outcomes. The 2021 World Health Organization (WHO) classification and advances in genome-wide DNA methylation profiling have transformed meningioma classification by incorporating molecular features into diagnostic and prognostic assessment. This narrative review summarizes current evidence on the prognostic value of transcriptomic profiling within an integrated molecular framework. Methods A structured literature search was conducted in PubMed/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for peer-reviewed studies published from January 2015 to Jul 2026. Search terms included meningioma, transcriptomics, gene expression profiling, RNA sequencing, DNA methylation, epigenomics, prognosis, recurrence, and biomarkers. Reference lists of landmark studies, consensus statements, and systematic reviews were manually screened to identify additional relevant publications, including a small number of foundational pre-2015 studies. 251 records were identified and 58 studies were included in the narrative synthesis. Results DNA methylation profiling consistently defines stable molecular subclasses and detects prognostically important copy-number alterations, such as 1p and 14q losses, while RNA sequencing captures dynamic biological processes and functional tumor states. Transcriptomic analyses identify three principal molecular phenotypes, which represent a synthesis across research groups rather than a single universally accepted classification: a favorable metabolic/differentiated subtype, an intermediate-risk immune-enriched subtype with immunosuppressive signaling, and an aggressive hypermitotic subtype driven by FOXM1 and E2F activation. In retrospective cohorts, integrating transcriptomic and methylation data improved risk stratification beyond WHO grade, including among histologically grade 1 and 2 tumors, whereas TERT promoter mutation and homozygous CDKN2A/B deletion define WHO grade 3 irrespective of histology. Conclusion Combined transcriptomic and DNA methylation profiling may enhance prognostication and postoperative risk stratification and could inform surveillance and adjuvant treatment decisions. However, most supporting evidence is retrospective, prospective validation is limited, and molecularly guided management is not yet a standard of care. Targeted therapies, immunotherapy, and liquid biopsy-based monitoring remain largely investigational. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Jafari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: